Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer
Lara Paracchini,Laura Mannarino,Chiara Romualdi,Riccardo Zadro,Luca Beltrame,Ilaria Fuso Nerini,Paolo Zola,Maria E Laudani,Eva Pagano,Livia Giordano,Robert Fruscio,Fabio Landoni,Silvia Franceschi,Maria L Dalessandro,Vincenzo Canzonieri,Luca Bocciolone,Domenica Lorusso,Cristina Bosetti,Francesco Raspagliesi,Isabella M G Garassino,TOWARDS group,Maurizio D'Incalci,Sergio Marchini
DOI: https://doi.org/10.1126/scitranslmed.adi2556
2023-12-06
Abstract:Late diagnosis and the lack of screening methods for early detection define high-grade serous ovarian cancer (HGSOC) as the gynecological malignancy with the highest mortality rate. In the work presented here, we investigated a retrospective and multicentric cohort of 250 archival Papanicolaou (Pap) test smears collected during routine gynecological screening. Samples were taken at different time points (from 1 month to 13.5 years before diagnosis) from 113 presymptomatic women who were subsequently diagnosed with HGSOC (pre-HGSOC) and from 77 healthy women. Genome instability was detected through low-pass whole-genome sequencing of DNA derived from Pap test samples in terms of copy number profile abnormality (CPA). CPA values of DNA extracted from Pap test samples from pre-HGSOC women were substantially higher than those in samples from healthy women. Consistently with the longitudinal analysis of clonal pathogenic TP53 mutations, this assay could detect HGSOC presence up to 9 years before diagnosis. This finding confirms the continual shedding of tumor cells from fimbriae toward the endocervical canal, suggesting a new path for the early diagnosis of HGSOC. We integrated the CPA score into the EVA (early ovarian cancer) test, the sensitivity of which was 75% (95% CI, 64.97 to 85.79), the specificity 96% (95% CI, 88.35 to 100.00), and the accuracy 81%. This proof-of-principle study indicates that the early diagnosis of HGSOC is feasible through the analysis of genomic alterations in DNA from endocervical smears.